Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Merck & Co., Inc.

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Merck Reports Strong Progress in ESG Focus Areas
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Present New Data at ESMO 2022 Congress From Its Broad Oncology Portfolio and Promising Pipeline, Demonstrating Commitment to Improving Long-Term Survival in Multiple Types of Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
LYNPARZA® (olaparib) Approved in Japan as Adjuvant Treatment for Patients With BRCA-Mutated, HER2-Negative High Recurrent Risk Breast Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Receives Fast Track Designation from the U.S. FDA for MK-2060, an Investigational Anticoagulant Therapy
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
LYNPARZA® (olaparib) Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Second-Quarter 2022 Financial Results
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Fourth-Quarter 2022 Dividend
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Provides Update on Phase 3 KEYNOTE-412 Trial in Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and Orion Announce Global Collaboration for the Development and Commercialization of ODM-208, an Investigational Steroid Synthesis Inhibitor for the Treatment of Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces the Launch of the Merck Digital Sciences Studio to Help Healthcare Startups Quickly Bring their Innovations to Market
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Hold Second-Quarter 2022 Sales and Earnings Conference Call July 28
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
LYNPARZA® (olaparib) Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent Patients (≥12 Years of Age) With Stage IIB or IIC Melanoma Following Complete Resection
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
CDC’s ACIP Unanimously Votes to Provisionally Recommend Use of Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) as an Option for Pneumococcal Vaccination in Infants and Children
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Results From Phase 3 PROpel Trial of LYNPARZA® (olaparib) Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM Evidence
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces that Chirfi Guindo will Lead Marketing for Merck Human Health
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company’s Investigational Pneumococcal Conjugate Vaccine for Adults
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Stage IB (≥4 centimeters)-IIIA Non-Small Cell Lung Cancer Following Complete Surgical Resection
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Participate in the 2022 Goldman Sachs 43rd Annual Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and Ridgeback Announce New Data For Investigational LAGEVRIO™ (molnupiravir) From Phase 3 MOVe-OUT Study
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Hold Investor Event to Highlight Oncology Portfolio and Pipeline
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Adjuvant Treatment With Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Statistically Significant & Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients With Resected Stage IIB or IIC Melanoma in Phase 3 KEYNOTE-716 Trial
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Third-Quarter 2022 Dividend
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced or Early-Stage Triple-Negative Breast Cancer at High Risk of Recurrence
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.